MDGL Stock Overview
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Madrigal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$193.33 |
| 52 Week High | US$322.67 |
| 52 Week Low | US$119.76 |
| Beta | -0.44 |
| 1 Month Change | -25.30% |
| 3 Month Change | -14.44% |
| 1 Year Change | -38.04% |
| 3 Year Change | 42.05% |
| 5 Year Change | 80.55% |
| Change since IPO | 1,804.71% |
Recent News & Updates
Recent updates
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Apr 24Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
Mar 15Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
Feb 07Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Dec 20
We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Aug 05Madrigal: Buy And Hoard Before Q4 Data Readout
Aug 04Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout
Jul 08Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 11Madrigal: NASH Data In Q4 Is The Key
Apr 19We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Feb 24Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come
Jan 31Madrigal: Powerful Catalyst Approaching
Jan 09We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Nov 08We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Jul 26Madrigal Pharmaceuticals: Leading The NASH Innovation
May 05Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation
Apr 12We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth
Dec 28
Madrigal Pharma: A Look At The Early MAESTRO Trial Data
Nov 27Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow
Nov 17Madrigal Pharmaceuticals EPS misses by $0.40
Nov 05Shareholder Returns
| MDGL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.8% | -0.2% | 2.9% |
| 1Y | -38.0% | -1.0% | 22.2% |
Return vs Industry: MDGL underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: MDGL underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| MDGL volatility | |
|---|---|
| MDGL Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MDGL's share price has been volatile over the past 3 months.
Volatility Over Time: MDGL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 376 | Bill Sibold | www.madrigalpharma.com |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. Fundamentals Summary
| MDGL fundamental statistics | |
|---|---|
| Market cap | US$4.06b |
| Earnings (TTM) | -US$373.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.9x
P/E RatioIs MDGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDGL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$373.63m |
| Earnings | -US$373.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -17.80 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 28.5% |
How did MDGL perform over the long term?
See historical performance and comparison